1 / 9

Ira M. Longini, Jr. Center for Statistical and Quantitative Infectious Diseases ( CSQUID )

Workshop on the immunological basis of vaccine efficacy Vaccine and Infectious Disease Institute December 14, 2009. Ira M. Longini, Jr. Center for Statistical and Quantitative Infectious Diseases ( CSQUID ) Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research Center and

dolph
Download Presentation

Ira M. Longini, Jr. Center for Statistical and Quantitative Infectious Diseases ( CSQUID )

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Workshop on the immunological basis of vaccine efficacyVaccine and Infectious Disease InstituteDecember 14, 2009 Ira M. Longini, Jr. Center for Statistical and Quantitative Infectious Diseases (CSQUID) Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research Center and The University of Washington Seattle Washington

  2. The State of Vaccinology • We need immune markers for vaccine protect against infection, disease and transmission. • We need to predict vaccine efficacy and effectiveness as well as indirect effectiveness from immunogenicity data. • Up until now, estimation of VE has been an empirical science based on phase III vaccine trials

  3. Guiding PrinciplesUp Until Now • We only care if vaccines work • We don’t care how they work • Problems with this • Need phase III trials for licensure • Sometimes immunological bridging works • So far, we have failed to develop truly effective vaccines for complex infections and mutagenic agents, e.g., • Malaria • TB • HIV • Flu

  4. Solution • Identify and quantify correlates of protection and surrogates of efficacy • Humoral (antibody) level • Cell mediated immunity • Need within host models of the immune response coupled with transmission models • Need phase III human trials where both immunological and clinical data available on same subjects • Animal models

  5. Today’s Workshop • Session I • Statistical Basics • Session II - III • Immune memory and dynamics of the immune response • Session IV • T – cell based vaccines

  6. Tuesday Morning • Informal discussion of workshop concepts • 10 am - noon • M5-C815 Arnold Building

  7. The End

More Related